Form 4: NewAmsterdam Pharma Co N.V. Executive Acquires and Disposes of Shares

Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V., reports acquisition and disposal of ordinary shares and restricted stock units on March 26, 2025.

Summary

• On March 26, 2025, Louise Frederika Kooij, the Chief Accounting Officer of NewAmsterdam Pharma Co N.V., engaged in transactions involving the company's securities.
• Kooij acquired 8,269 ordinary shares at a price of $0.
• Simultaneously, Kooij disposed of 8,269 ordinary shares.
• These transactions also involved restricted stock units (RSUs), with Kooij acquiring and disposing of 8,269 RSUs each.
• The RSUs were granted as earnout RSUs related to a business combination agreement and vested fully upon grant.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a standard regulatory filing detailing transactions by an officer. There is no inherent positive or negative implication.

Positives

• The granting of RSUs indicates alignment of executive compensation with company performance and milestones.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, but are unlikely to significantly alter the company's valuation.

Key Dates

Keywords

NewAmsterdam Pharma, NAMS, Form 4, Beneficial Ownership, Louise Kooij, Chief Accounting Officer, Ordinary Shares, Restricted Stock Units, RSUs, Acquisition, Disposal, Transaction